Fatou with Dr. Nathaniel Chin on the New FDA Approved Alzheimer‘s Drug, Aducanumab/Aduhelm

In this episode, I had the honor of speaking with Dr. Nathaniel Chin about Aducanumab/Aduhelm the new FDA approved Alzheimer's drug. Dr. Chin is an assistant professor in the division of geriatrics and gerontology. Dr. Chin received his undergraduate and medical degrees from the University of Wisconsin-Madison. He then went to the University of California-San Diego for his internal medicine residency. After completing his residency he spent the next two years working as a Hospitalist for Kaiser Permanente before returning to WI in 2015 to help his mother provide care for his father who had been diagnosed with Alzheimer’s disease. He completed his geriatric fellowship in 2016 and spent another year in a dementia research fellowship within geriatrics. He was then hired as an assistant professor. Dr. Chin sees patients in the UW Health Memory Clinic and in addition to providing diagnoses he focuses on palliative care in chronic disease management. In addition to his clinical and research work, he is the medical director of the WI Alzheimer’s Disease Research Study and the Wisconsin Registry for Alzheimer’s Prevention Study, the Co-Leader of the ADRC Clinical Core, as well as the Associate Director of the Geriatric Memory Clinics at UW-Health. He also serves on the board of the WI Alzheimer’s Association and the Alzheimer’s Foundation of America. Dr. Chin is a Co-Investigator on 5 NIH grants, with one of them focused biomarker disclosure. He presents frequently on the topics of AD and geriatrics and in the past 3 years has given over 55 presentations at local, regional and national conferences. He has created over 100 podcasts on AD research and caregiving topics under his podcast called Dementia Matters. 

Please tune in for a great learning session on this new drug and more.